MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager

Statement of Purpose
Guidelines for Authors
Editorial Board

Recent Issues

August 2014


Letters to the Editor

In-House Drug Diversion by Hospital Personnel / Quality Measures at Compounding Facilities

Health Care & Law

Legal Risk Management Opportunities, Pharmacy Practice, and P&T Committees

Part 1: Deconstructing Dispensing Errors

A comprehensive analysis of malpractice claims experience from a professional liability insurer, Healthcare Providers Service Organization, can help P&T committees better understand the risks and challenges they encounter each day.
James O’Donnell, PharmD; and F. Randy Vogenberg, RPh, PhD

Are Specialty Drug Prices Destroying Insurers and Hurting Consumers?

A Number of Efforts Are Under Way to Reduce Price Pressure

Organizations are trying to address the high cost of “specialty” medications that treat conditions such as cancer, hepatitis C, and multiple sclerosis. While comprising less than 1% of U.S. prescriptions, these drugs now account for 27% of pharmacy spending.
Stephen Barlas

Irritable Bowel Syndrome: Current and Emerging Treatment Options

Irritable bowel syndrome, a functional gastrointestinal disorder of uncertain pathophysiology, affects up to 55 million Americans. Medications available or in development include antispasmodics, antidepressants, and antidiarrheals.
Lauren Peyton, PharmD, CDE; and Joy Greene, PharmD

Meeting Highlights

European Hematology Association

Attendees at the 19th Congress of the European Hematology Association in Milan, Italy, heard reports on new therapies for acute myeloid leukemia, chronic lymphocytic leukemia, β-thalassemia, multiple myeloma, and polycythemia vera.
Walter Alexander

Pipeline Plus

Ulcerative Colitis and Crohn’s Disease

As new drugs emerge from the pipeline for the nearly 2 billion patients globally diagnosed with ulcerative colitis and Crohn’s disease, sales of therapies for these conditions are expected to increase from $7.35 billion today to $11.05 billion in 2022.
Kunj Gohil, PharmD, RPh; and Brielle Carramusa


Medication Errors

Oops, Sorry, Wrong Patient!

A Patient Verification Process Is Needed Everywhere, Not Just at the Bedside

Matthew Grissinger, RPh, FASCP

Prescription: Washington

HHS Alters Formulary Exception Policy for 2015

QHPs Must Respond Within 24 Hours to “Expedited” Requests

Stephen Barlas

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, and updates

Pharmaceutical Approval Update

Vedolizumab (Entyvio) for ulcerative colitis and Crohn’s disease; dalbavancin (Dalvance) for acute bacterial skin and skin structure infections; and antihemophilic factor, recombinant (Eloctate) for hemophilia A
Marvin M. Goldenberg, PhD, RPh, MS

Drug Forecast

Tedizolid Phosphate (Sivextro)

A Second-Generation Oxazolidinone to Treat Acute Bacterial Skin and Skin Structure Infections

Elaine Wong, PharmD, BCPS; and Saba Rab, PharmD, BCPS